Chicago Partners Investment Group LLC Acquires 245,199 Shares of DENTSPLY SIRONA Inc. $XRAY

Key Points

• Chicago Partners Investment Group increased its DENTSPLY SIRONA stake by 1,130.7%, buying 245,199 shares in the third quarter to hold 266,884 shares valued at about $2.52 million. Institutional investors own 95.7% of the stock.
• DENTSPLY SIRONA’s third-quarter results missed estimates: adjusted EPS was $0.29 versus $0.31 expected, and revenue was $836 million versus about $862 million expected, down 7.5% year over year.
• The company cut its 2026 adjusted EPS outlook to $1.20–$1.30 and forecast revenue of $3.5 billion, below analyst expectations. Analysts’ consensus rating is “Hold,” with a $12.64 average price target.

Chicago Partners Investment Group LLC increased its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 1,130.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 266,884 shares of the medical instruments supplier's stock after acquiring an additional 245,199 shares during the quarter. Chicago Partners Investment Group LLC owned approximately 0.13% of DENTSPLY SIRONA worth $2,517,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of DENTSPLY SIRONA during the second quarter worth about $283,405,000. Southpoint Capital Advisors LP bought a new position in DENTSPLY SIRONA in the 1st quarter worth about $116,000,000. Edmond DE Rothschild Holding S.A. bought a new position in DENTSPLY SIRONA in the 2nd quarter worth about $47,780,000. Paradigm Capital Management Inc. NY acquired a new stake in shares of DENTSPLY SIRONA in the second quarter valued at approximately $39,775,000. Finally, Bank of America Corp DE acquired a new stake in shares of DENTSPLY SIRONA in the second quarter valued at approximately $31,001,000. 95.70% of the stock is currently owned by institutional investors.

Key Stories Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Growth at Wellspect provided some support amid weakness elsewhere in the business. XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut
• Negative Sentiment: Q3 adjusted earnings of $0.29 per share fell short of the $0.31 analyst consensus, while revenue of $836 million missed the roughly $862 million estimate. Revenue declined about 7.5% year over year, and EPS was lower than the $0.37 reported a year earlier. Third-quarter and nine-month results
• Negative Sentiment: The company cut its 2026 adjusted EPS guidance to $1.20–$1.30, below the $1.47 analyst consensus, and forecast revenue of $3.5 billion versus expectations of $3.6 billion. The lower outlook reinforces concerns about continued demand weakness. XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut

Wall Street Analyst Weigh In

XRAY has been the subject of several recent analyst reports. Barrington Research decreased their price target on DENTSPLY SIRONA from $15.00 to $13.00 and set an "outperform" rating for the company in a research note on Monday, October 26th. Piper Sandler decreased their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Friday, October 9th. Barclays raised their target price on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an "underweight" rating in a research note on Monday, August 24th. Bank of America restated a "buy" rating on shares of DENTSPLY SIRONA in a research report on Friday. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research note on Friday, October 30th. Three analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $12.64.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $9.46 on Friday. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. The business's 50-day moving average price is $9.60 and its 200 day moving average price is $11.28. DENTSPLY SIRONA Inc. has a 52-week low of $8.14 and a 52-week high of $14.76. The firm has a market cap of $1.89 billion, a P/E ratio of -15.26, a PEG ratio of 1.27 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by ($0.02). DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $836.00 million during the quarter, compared to analyst estimates of $861.68 million. During the same period in the previous year, the company posted $0.37 earnings per share. DENTSPLY SIRONA's revenue was down 7.5% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. As a group, sell-side analysts predict that DENTSPLY SIRONA Inc. will post 1.39 earnings per share for the current fiscal year.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.